We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The European Commission has given marketing authorisation for Dupixent (dupilumab), the first targeted biologic in Europe to treat the most common form of eczema.